How do you account for dosimetric contributions from 177Lu-PNT2002 when planning SBRT?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Clinical Trials Session Presentation "177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial" by Dr. Amar Kishan.
1 Answer
Mednet Member
Radiation Oncology · David Geffen School of Medicine at UCLA
Answered on
This is challenging and will be a timely question. In this specific trial, we did perform timed SPECT/CT scans after 177Lu-PNT2002 to try to compute dose to various OARs (and tumor). It is difficult to model this, but there are some published references that allow one to estimate the dose contributi...
Join for free or sign in to see the full answer